Microbot Medical Inc. (NASDAQ:MBOT) Receives $7.50 Consensus Price Target from Analysts
by Scott Moore · The Cerbat GemShares of Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $7.50.
Separately, B. Riley Financial began coverage on shares of Microbot Medical in a research note on Tuesday, February 10th. They issued a “buy” rating for the company.
Get Our Latest Stock Report on MBOT
Institutional Trading of Microbot Medical
Several hedge funds have recently added to or reduced their stakes in MBOT. Beacon Capital Management LLC grew its position in Microbot Medical by 37.5% during the third quarter. Beacon Capital Management LLC now owns 22,000 shares of the biotechnology company’s stock worth $67,000 after buying an additional 6,000 shares in the last quarter. Cetera Investment Advisers raised its holdings in Microbot Medical by 38.8% in the 4th quarter. Cetera Investment Advisers now owns 29,313 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 8,201 shares in the last quarter. Cornerstone Advisory LLC bought a new stake in shares of Microbot Medical during the 3rd quarter valued at $30,000. Zacks Investment Management bought a new stake in shares of Microbot Medical during the 3rd quarter valued at $33,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Microbot Medical during the 3rd quarter worth $37,000. 16.30% of the stock is owned by institutional investors and hedge funds.
Microbot Medical Stock Performance
Shares of MBOT stock opened at $2.40 on Wednesday. The firm’s fifty day moving average price is $2.28 and its two-hundred day moving average price is $2.37. Microbot Medical has a 1 year low of $1.35 and a 1 year high of $4.67. The firm has a market capitalization of $161.18 million, a P/E ratio of -8.28 and a beta of 1.19.
Microbot Medical (NASDAQ:MBOT – Get Free Report) last released its earnings results on Thursday, March 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. As a group, equities research analysts forecast that Microbot Medical will post -0.71 EPS for the current fiscal year.
About Microbot Medical
Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.
Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.